FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer FDA OKs Upfront Pembro for Advanced HER2+ Gastric Cancer
The accelerated approval is for first-line use in combination with other agents for locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Gastric (Stomach) Cancer | Gastroenterology | Hematology | HER2